BRAF and metastatic melanoma: The use of small molecules to inhibit the proteins involved in re-sensitization of melanoma cells harboring mutant BRAF to BRAFi/MEKi would enable future application of new drug combinations that could enhance sensitivity and/or delay resistance to targeted therapy in metastatic melanoma.